Clear market notes built around the JSE, the rand, and what matters locally.

2026-07-19 11:35 • The Motley Fool Positive Axe Cap view: Selective

McDonald's stock has fallen 20% from its February peak due to inflation pressuring customers toward lower-margin value items, but the company is one year away from achieving Dividend King status with 49 consecutive years of dividend increases. Despite current headwinds, the article suggests this pullback presents a buying opportunity for a well-established brand with a reliable dividend history.

Axe note: McDonald's 49-year run of rising dividends hits a near milestone amid a market pullback, tempting income seekers even outside the U.S.

2026-07-19 11:27 • The Motley Fool Positive Axe Cap view: Selective

Amazon's $200 billion AI investment is backed by strong fundamentals, including its Trainium chip business running at a $20 billion annual revenue pace with $225 billion in pre-committed customer contracts. The custom chip operation is growing at triple-digit percentages and offers better performance-per-dollar than competitors, allowing Amazon to build a more controlled and cost-efficient AI supply chain.

Axe note: Amazon’s massive AI spending is underpinned by real revenue and growth, a signal worth watching through the rand lens.

2026-07-19 11:15 • The Motley Fool Neutral Axe Cap view: Selective

Pfizer's stock has fallen over 50% from late 2021 highs, pushing its dividend yield to a historically high 6.9%. While the company faces normal industry headwinds including upcoming patent expirations and disappointing new drug development, management remains committed to protecting the dividend. The company is taking steps to address challenges, including acquiring a weight-loss drug candidate after dropping its own GLP-1 drug. More aggressive dividend investors may find Pfizer's valuation compelling despite risks.

Axe note: Pfizer’s plunge has pushed its dividend yield near 7%, tempting income investors despite looming patent cliffs and pipeline challenges.